Latest News and Press Releases

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "IP (Intellectual Property) Due Diligence & Freedom to Operate in Practice Training Course" training has been added to ResearchAndMarkets.com's...

Dublin, May 12, 2025 (GLOBE NEWSWIRE) -- The "Annual Update for Senior Trade Mark & Design Administrators Training Course (London, United Kingdom - September 8-9, 2025)" has been added to ...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Building and Managing a Patent Portfolio to Best Support your Business Training Course" training has been added to ResearchAndMarkets.com's offering. ...

Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided...

Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "IP (Intellectual Property) Due Diligence & Freedom to Operate in Practice Training Course (ONLINE EVENT: March 6-7, 2025)" has been added to ...

Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Hybrid Bonding - Patent Landscape Analysis 2024" report has been added to ResearchAndMarkets.com's offering. Hybrid bonding technology emerged in...

Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Annual Update for Senior Trade Mark & Design Administrators Training Course" conference has been added to ResearchAndMarkets.com's offering. This...

Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...